1. G.Dubin Enhanced Immunogenicity of a Candidate Human Papillomavirus (HPV) 16/18 L1 Virus Like Particle (VLP) Vaccine with Novel AS04 adjuvant in Pre-teens/Adolescents (submitted, 2005)
2. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al.. Lancet 2006;367: 1247–55
3. Roden R, Wu T-C. Expert Rev Vaccines. 2003;2: 495–516.
4. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Proc Natl Acad Sci USA. 1992;89:12180–84.
5. Kirnbauer R, Taub J, Greenstone H, et al. J Virol. 1993;67:6929–6936
6. Stanley MA. Expert Rev Vaccines. 2003;2:381–9.
7. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccine. 1995;13:1509–14.
8. Bryan JT, Jansen KU, Lowe RS, et al. Med Virol. 1997;53:185–8.)
9. Walboomers JM, Jacobs MV, Manos MM, et al. J Pathol. 1999;189:12–19. 2. American Cancer Society. Available at: http://www.cancer.org. Accessed March 30, 2006.
10. Herrero R, Castellsagu_ X, Pawlita M, et al. J Natl Cancer Inst. 2003;95:1772–83.
11. World Health Organization. Geneva, Switzerland: World Health Organization; 1999:1–22.
12. Munger K, Baldwin A, Edwards KM, et al. J Virol. 2004;78:11451–60.
13. LL Villa Vaccine 24S1(2006) S1/23-S1/28
14. LL Villa et al Vaccine 24 (2006) 5571-5583
15. LL Villa et al British Journal of Cancer (2006) 95, 1459–66.
16. Jan H. Frazer et al The Pediatric Infectious Disease Journal, Vol.25 Number 2, 65–81.
Авторы
С.И.Роговская
ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной
медицинской помощи, Москва